Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection
J. Clin. Invest. Feng Lin, et al. 110:1269 doi:10.1172/JCI16086 [
Go to this article.]
Figure 3Whole-animal AChR levels in
Daf1–/– and
Daf1+/+ mice 48 hours after McAb-3 mAb injection. The bars (NI, noninjected; I, injected) show changes in levels normalized to noninjection levels.
Daf1–/–,
n = 8;
Daf1+/+,
n = 4. *
P > 0.05. The noninjection levels in the
Daf1–/– mice were not decreased relative to wild-type controls (0.213 vs. 0.160 pmol/g muscle).
